Compare InMode Ltd (INMD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs GeneDx Holdings Corp — how do they compare? InMode Ltd trades at $14.21 (market cap $809.93M), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is far larger — about 2.5× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and GeneDx Holdings Corp for 19 Days on average.
| INMD | WGS | |
|---|---|---|
Market Cap | $809.93M | $2.02B |
Volume | 365,490 | 734,640 |
Sector | Health | Health |
52-Week High | $16.62 | $167.51 |
52-Week Low | $12.76 | $34.51 |
Typical Hold Time | 28 Days | 19 Days |
Enterprise Value | $313.27M | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.08, up 0.5% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 11.63, gross margins of 76.52%, and consistent revenue around $370M. Recent news includes product innovation with Morpheus8 Cool launch and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
Outlook remains cautious with analyst consensus divided (45% Buy, 55% Hold) amid cyclical softness. Investment opportunity lies in potential acquisition premium and international growth, while risks include US sales decline and management capital allocation concerns. The stock faces near-term resistance at $14 with support at the same level.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
